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Abstract
The pattern of collagen cross-linking is tissue specific primarily determined by the extent of
hydroxylation and oxidation of specific lysine residues in the molecule. In this study, murine pre-
myoblast cell line, C2C12 cells, were transdifferentiated into osteoblastic cells by bone
morphogenetic protein (BMP)-2 treatment, and the gene expression of lysyl hydroxylases (LH1, 2a/
b and 3) and lysyl oxidase (LOX)/lysyl oxidase-like proteins (LOXL1–4), and the extent of
hydroxylysine were analyzed. After 24 hours of treatment, the expression of most isoforms were
upregulated up to 96 hours whereas LH2a and LOXL2 decreased with time. In the treated cells, both
hydroxyproline and hydroxylysine were detected at day 7 and increased at day 14. The ratio of
hydroxylysine to hydroxyproline was significantly increased at day 14. The results indicate that LHs
and LOX/LOXLs are differentially responsive to BMP-induced osteoblast differentiation that may
eventually lead to the specific collagen cross-linking pattern seen in bone.
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Introduction
Fibrillar type I collagen is the most abundant protein in vertebrates providing the basis for form
and connectivity of tissues and organs, but its post-translational modifications vary from tissue
to tissue. A number of studies have demonstrated that the specific post-translational
modifications are essential for the formation of functional fibrils in the respective tissues[1].
In bone, the specific pattern of lysine hydroxylation and covalent intermolecular cross-linking
is important to regulate the process of biomineralization [2–5]. Lysyl hydroxylases (LHs) and
lysyl oxidase (LOX)/LOX-like proteins (LOXLs) are two groups of enzymes that play critical
roles in determining the pattern collagen cross-linking. At present, 3 genes encoding for LH
(LH1, 2a/b, 3) and 5 for LOX/LOXL (LOX, LOXL1-4) have been identified and partially
characterized. It has been reported that mutations in some of these genes are partly associated
with inherited disorders, e.g. mutations in LH1 gene with the Ehlers-Danlos syndrome type VI
[6] and LH2 with the Bruck syndrome [7]. Recently, we have demonstrated that most isoforms
of LH [8,9] and LOX/LOXL [10] are expressed in osteoblastic cell line, MC3T3-E1 cells, and
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that LH2b is critical in determining collagen cross-linking pattern [8]. However, the
significance of the isoform expression and their regulatory mechanisms are still not well
understood.
Bone morphogenetic protein (BMP)-2, a member of the transforming growth factor beta (TGF-
β) superfamily, is one of the most potent osteogenic BMPs. It has been shown that BMP-2 is
capable of driving the murine pre-myoblast cell line C2C12 cells into osteoblastic lineage
(transdifferentiation) by suppressing the expression of myogenic genes and inducing that of
osteogenic genes [11]. Thus, this model has been widely used to study the molecular events
related to early osteoblast differentiation and BMP functions. Microarray analyses have
revealed that genes of the extracellular matrix proteins such as type I collagen, biglycan and
decorin were upregulated after BMP-2 treatment [12]. However, the response of collagen
modifying enzyme genes or their products (i.e. modified amino acids) has not been
investigated.
In this study, by employing this model, we examined the expression of genes for lysyl
hydroxylase (LH1, 2a/b and 3) and lysyl oxidase (LOX, LOXL1–4), and the extent of
hydroxylysine to obtain an insight into the significance of collagen post-translational
modifications in early osteoblast differentiation.
Materials and methods
Cell culture
C2C12 cells were purchased from American Type Culture Collection (CRL-1772) and
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Carlsbad. CA, USA)
containing 15 % Fetal Bovine Serum (FBS, Sigma, St. Louis, MO, USA), 100 U/ml penicillin
and 100 μg/ml streptomycin in a 5 % CO2 atmosphere at 37 °C. The cells were plated onto 35
mm dishes at a density of 8 × 104 cells/dish and cultured for 24 hrs. The culture medium was
then replaced with DMEM containing 5 % FBS with various concentrations (0, 50, 100, 150
ng/ml) of recombinant human BMP-2 (rhBMP-2, 355-BM/CF, R&D systems, Minneapolis,
MN, USA). Cell morphology was observed under an inverted light microscopy (ECLIPSE
TE300, Nikon, Tokyo, Japan) and subjected to the following analyses.
Alkaline Phosphatase (ALP) activity
After 4 days of culture, cell/matrix layer was washed with phosphate buffered saline (PBS)
and lysed with 300 μl of tris buffer saline (TBS) containing 0.1 % Triton-X. ALP activity was
measured using Alkaline Phosphatase Yellow (pNPP; p-nitrophenylphosphate) Liquid
Substrate System for ELISA (Sigma, St. Louis, MO, USA) according to the manufacturer’s
protocol. The reaction was terminated with 3 N NaOH to a final concentration of 0.5 N NaOH
and the pNP production was measured by absorbance at 405 nm using a 96-well plate reader
(PowerWave X 340, Bio Tek instruments, Winooski, VT, USA). The protein concentration
was determined by a DC Protein Assay kit (Bio-Rad, Hercules, CA, USA) and ALP activity
was calculated as mol of pNP/min/total protein [13].
Quantitative real-time Polymerase Chain Reaction (PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) after 0, 16, 24,
48, 72 and 96 hours of rhBMP-2 treatment and the first-strand cDNA was synthesized using
an Omniscript Reverse Transcriptase Kit (Qiagen, Valencia, CA, USA). The mRNA expression
levels of myogenic genes, i.e. myogenin and MyoD, osteogenic genes, i.e. alkaline phosphatase
2 (Akp2), core binding factor alpha 1 (Cbfa1), osterix (OSX), and type-1 collagen α1 chain
(Col1a1), and isoforms of collagen modifying enzyme genes, i.e. LH1, LH2, LH3, LOX,
LOXL1, LOXL2, LOXL3 and LOXL4, were quantitatively analyzed by real-time PCR. It was
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performed by the ABI Prism 7000 Sequence detection system (Applied Biosystems, Foster
City, CA, USA) using the sequence specific primers. Primers used are as follows; myogenin
(ABI assay No. Mm 00446194_m1), MyoD (Mm 00440387_m1), Akp2 (Mm 00475831_m1),
Cbfa1 (Mm 00501578_m1), OSX (Mm 00504574_m1), Col1a1 (Mm 00801666_g1), LH1
(Mm 00599925_m1), LH2 (Mm 00478767_m1), LH3 (Mm 00478798_m1), LOX (Mm
00495386_m1), LOXL1 (174595), LOXL2 (Mm 00804740_m1), LOXL3 (Mm
00442953_m1), LOXL4 (Mm 00446385_m1), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (4308313). The samples were analyzed in triplicate and two independent
experiments were performed to confirm reproducibility of the results. The mRNA expression
levels relative to GAPDH were determined and the fold changes were calculated using the
values obtained before rhBMP-2 addition (0 hour) as a calibrator by means of 2−ΔΔCT method
on each time point [14]. For OSX and Akp2, since the expression were not detected without
the addition of rhBMP-2, the value obtained at after 16 hours of rhBMP-2 treatment was used
as a calibrator.
Reverse Transcription (RT)-PCR
Specific primers for LH2 were designed to determine the two known splicing variants; forward
primer, 5′GAAAGGAACTATTTTGTCCGTGATA3′ (position1440–1464); and reverse
primer, 5′GGGATCTATAAATGACACTGCAAT3′ (position1575–1599). This set of primers
amplifies both LH2a (without an insert of 63 bp exon 13A) and LH2b (with the splice insert)
identifying the former as a 158 bp fragment and the latter a 221 bp fragment [6]. A set of
GAPDH primers; forward, 5′ACCACAGTCCATGCCATCAC3′, reverse, 5′
TCCACCACCCTGTTGCTGTA3′ were also designed to use as an internal control. RT-PCR
amplifications were performed by HotStarTaq DNA polytmerase (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instruction. The optimal number of PCR cycles was
selected for each amplification; 35 cycles for LH2a and GAPDH, and 22 cycles for LH2b. The
PCR products were then resolved by 12% polyacrylamide gel electrophoresis (PAGE) and
analyzed.
Amino acid analysis
C2C12 cells were cultured with or without the addition of 100 ng/ml of rhBMP-2 in the
presence of 50 μg/ml of ascorbic acid and, at day 7 and 14, cell/matrix layer was subjected to
amino acid analysis as described[15]. Briefly, cultured cells/matrix layer was scraped, washed
with PBS and distilled water, lyophilized, hydrolyzed with 6N HCl in vacuo at 105°C for 22
hrs and dried. The hydrolysates were dissolved in distilled water and subjected to amino acid
analysis by HPLC (Varian 9050/9012; Varian, Walnut Creek, CA, USA). The content of
hydroxyproline (Hyp) and hydroxylysine (Hyl) were expressed as res/1,000 amino acids, and
the ratio of Hyl to Hyp was calculated and expressed as a percentage. The analysis was done
in duplicate for two sets of experiments.
Results
Transdifferentiation from Myoblasts to Osteoblasts
The myotubes were observed in C2C12 cells after reaching the confluence at day 4 (Fig. 1a).
When treated with rhBMP-2, however, the cell morphology was significantly changed into an
osteoblast-like round shape in 4 days (Fig. 1c) as previously reported [9]. At day 14, the
formation of myotubes became more prominent in the untreated cells (Fig. 1b) in contrast to
the rhBMP-2 treated cells which formed cell/matrices layer (Fig. 1d). In addition, ALP activity
at day 4 was increased with rhBMP-2 treatment in a dose dependent manner indicating the cell
lineage was converted from myoblasts to osteoblasts (Fig. 1e).
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The expression of a myogenic gene, myogenin, was continuously downregulated with
rhBMP-2 treatment but was markedly increased with the progression of culture in the untreated
cells (Fig. 1f). MyoD, another myogenic gene, showed a transient increase at 16 hours then
decreased thereafter in the treated cells but it was gradually increased with time in the untreated
group (Fig. 1g) as previously reported [11]. Two genes encoding OSX and Cbfa1,
transcriptional factors critical for osteoblast differentiation, were significantly upregulated with
rhBMP-2 treatment. The expression of OSX was detected at 16 hours of treatment, increased
at 48 hours and then gradually decreased (Fig. 1h). It was not detected in the untreated cells at
any time points analyzed. Cbfa1 showed an increase at 48 hours and continued to increase
thereafter (Fig. 1i). Akp2 was detected only in the treated cells at 16 hours and markedly
increased thereafter (Fig. 1j). It was not detected at any time points in the untreated cells.
Expression of LH and LOX isoforms, and type I collagen
In the treated cells, the Col1a1 (Fig 2a) expression was significantly increased at 48 hours and
continued to increase thereafter whereas such increases were not seen in the untreated cells.
The expression of all LH and LOX isoforms changed with rhBMP-2 treatment (Fig. 2b–i). Of
LH isoforms, LH1 showed the most and significant increase reaching to a 4.0 fold increase at
96 hours of treatment (Fig. 2b). The expression of LH2, after a transient decrease at 24 hours,
showed a 1.5 fold increase at 96 hours (Fig 2c). LH3 expression decreased until 24 hours of
treatment, then gradually increased and returned to the initial expression level (time 0) (Fig.
2d). The expression of LOX isoforms including LOX, LOXL1, LOXL3 and LOXL4 were all
upregulated with rhBMP-2 treatment (Fig. 2e, f, h, i). In particular, LOX was highly responsive
to the treatment reaching to a 6 fold increase at 96 hours of treatment. In the untreated cells,
LOX expression was slightly suppressed with time. The expression of LOXL1 was upregulated
in both untreated and treated cells after 24 hours of treatment but the latter showed slightly
higher expression levels compared to the former. LOXL3 and 4 showed a similar pattern in
the treated cells starting to increase after 24 hours of treatment and reached at a 2-fold increase
at 96 hours whereas no significant changes were observed in the untreated cells. Of LOX
isoforms, only LOXL2 expression was continuously diminished with the treatment while it
increased in the untreated cells (Fig. 2g).
Expression of LH2 alternative splicing variant
Both LH2 splicing variants, LH2a and b, were expressed in C2C12 cells without rhBMP-2
treatment and the levels did not significantly change up to 96 hours of culture. With the
treatment, however, LH2b expression was significantly enhanced while LH2a markedly
diminished (Fig. 3). These opposite effects may explain a moderate increase of LH2 expression
where both isoforms were not distinguished (Fig 2c).
Amino acid analysis
In the untreated cells, Hyp and Hyl were undetectable (<0.05 nmol) both at 7 and 14 days.
However, with rhBMP-2 treatment, both amino acids became detectable at day 7 and
significantly increased at day 14. The ratio of Hyl to Hyp was also significantly increased by
~2 fold at day 14 in comparison to that of day 7 (Table 1).
Discussion
Pre-myoblast cell line, C2C12 cells, transdifferentiate from myoblasts to osteoblasts with
rhBMP-2 treatment by changing the gene expression phenotype [11,12,16]. Balint et al [12]
described the response of C2C12 cells to rhBMP-2 at four stages, 1. activation and repression
of non-osteogenic developmental systems (1–4 h), 2. remodeling cell architecture (4–8 h), 3.
commitment to osteogenesis (8–16 h) and 4. establishment of the bone phenotype (16–24 h).
Myogenic genes were well expressed at stage 1, osteoblastic transcriptional factors, i.e. Cbfa1,
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OSX at stage 3, major extracellular matrix proteins, i.e. type I collagen, biglycan, decorin at
stage 4. Though the genetic responses of myogenic and osteogenic genes were somewhat
slower in our study than those reported by Balint et al (e.g. significant increases in Col1a1,
Akp2, expression were observed only at 48 hours after treatment), the overall pattern and order
of expression were similar. The delayed response may be due to the differences in culture
conditions, e.g. rhBMP-2 concentrations (100 ng/ml vs. 300 ng/ml), means of assay (real-time
PCR vs. microarray), etc.
It has now become clear that for a single post-translational modification of collagen such as
lysine hydroxylation or oxidative deamination, several isoforms of the specific enzyme group
can be involved [17]. The differential gene expression of various isoforms may lead to the
well-documented tissue specific cross-linking pattern [1]. Though certain cytokines/growth
factors have been demonstrated to regulate gene expression/protein synthesis of LH and LOX
[18–21], the molecular events and regulatory mechanisms for their isoforms are still poorly
understood. The present study represents, to the best to our knowledge, the first to demonstrate
the response of the known LH and LOX isoforms to rhBMP-2 induced osteoblast
differentiation.
After 24 hours of rhBMP-2 treatment, the expression of most isoforms of LH and LOX, except
LH2a and LOXL2, were upregulated suggesting their positive involvement in the process of
early osteoblast differentiation. It is of interest to note that the expression levels of both LH2a
and LOXL2 are very low or undetectable in differentiating MC3T3-E1 osteoblast [8,10]. The
LOXL2 mRNA expression is also downregulated in bone marrow stromal cells during
differentiation [22]. Though the functions of LH2a and LOXL2 in osteoblast are still not well
understood, these particular forms of LH and LOXL may be associated with certain cell types
or pathological states [23,24] but likely not with osteoblast phenotypes. It is also of interest to
note that both LH1 and LOX genes were upregulated by rhBMP-2 treatment as early as 16
hours of treatment. These are significantly earlier than that of type I collagen, i.e. 48 hours,
suggesting that those collagen modifying enzymes may need to be synthesized before collagen
itself. The properly modified collagen then forms the functional fibrils in the respective tissues,
thus, underscoring the importance of collagen modifications.
In this study, we also analyzed the extent of Hyl and Hyp in the cell/matrix layer. Both amino
acids were not detectable at day 7 and 14 in the untreated cells. However, in the treated cells,
both were detected at day 7 and significantly increased at day 14. This increase was not detected
in the absence of ascorbic acid (data not shown) indicating a critical role of ascorbic acid in
collagen biosynthesis [25]. Interestingly, the ratio of Hyl to Hyp was significantly increased
from day 7 (8.4%) to 14 (14.2%) indicating that the extent of Lys hydroxylation of collagen
synthesized was increased during this period. The ratio at day 14 is comparable to that of bone
collagen [26]. The data also indicate that it requires some time for transdifferentiating cells to
deposit collagen matrix with appropriate post-translational modifications. Due to the limited
quantity of collagen, collagen cross-links were not measured.
Taken together, the results of this study indicate that the genes of collagen modifying enzymes,
groups of LH and LOX/LOXL, are differentially responsive to BMP-2 that may lead to specific
cross-linking pattern of collagen important for bone formation.
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Transdifferentiation of C2C12 cells from myoblasts to osteoblasts induced by rhBMP-2. The
cells were cultured for 4 (a, c) or 14 days (b, d), without (a, b) or with 100 ng/ml of rhBMP-2
(c, d) and observed (X 40). Arrowheads indicate the presence of myotubes. At 4 days of
treatment, cell shape changed to osteoblast-like round shape (c). At day 14, typical myotubes
were well formed without rhBMP-2 treatment (b) whereas cell/matrices layer was clearly
formed with the treatment (d). At day 4, ALP activity was increased with rhBMP-2 treatment
in a dose dependent manner (e). mRNA expression of myogenic and osteogenic genes with or
without rhBMP-2 treatment at various time points analyzed by real-time PCR (f–j). Note that
osteogenic genes were upregulated (h–j) whereas myogenic genes suppressed (f,g) with time.
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mRNA expression of type 1 collagen and collagen modifying enzymes with or without
rhBMP-2 treatment at various time points analyzed by real-time PCR (ai). After 24 hours, only
LOXL2 expression was decreased while the others were increased with time. Note that LH2
variants (LH2a and b) were not distinguished by this assay (see Fig 3). See text for the
description of each abbreviation.
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mRNA expression of LH2a and LH2b splicing variants in response to rhBMP-2 analyzed by
RT-PCR. LH2a, identified as a 158 bp PCR product was decreased with rhBMP-2 treatment
while LH2b, identified as a 221 bp fragment, increased with time.
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Table 1
Hydroxyproline and hydroxylysine in the cell/matrix layer
day 7 7 14 14
rhBMP-2 − + − +
Hyp* nd 1.72±0.28 nd 3.55±0.14
Hyl* nd 0.14±0.01 nd 0.51±0.05
Hyl/Hyp (%) − 8.4±0.8 − 14.2±0.1
*
Values of Hyp and Hyl are shown as res/1,000 of total amino acids.
nd; not detectable, (< 0.05 nmol)
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